GMED GLOBUS MEDICAL INC

NYSE globusmedical.com


$ 85.22 $ 0.14 (0.16 %)    

Wednesday, 12-Nov-2025 13:32:01 EST
QQQ $ 620.76 $ -4.02 (-0.64 %)
DIA $ 483.31 $ 2.75 (0.57 %)
SPY $ 683.52 $ -1.24 (-0.19 %)
TLT $ 90.14 $ 0.19 (0.22 %)
GLD $ 387.19 $ 7.01 (1.84 %)
$ 84.94
$ 84.96
$ 85.15 x 100
$ 85.28 x 50
$ 84.79 - $ 86.14
$ 51.79 - $ 94.93
2,947,733
na
11.37B
$ 1.01
$ 26.83
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 11-05-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-17-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-17-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-20-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-21-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 07-27-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-globus-medical-raises-price-target-to-114

Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $106 to...

 expedia-sandisk-and-penumbra-are-among-the-top-10-large-cap-gainers-last-week-nov-3-nov-7-are-the-others-in-your-portfolio

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad do...

 rbc-capital-maintains-outperform-on-globus-medical-raises-price-target-to-92

RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $88...

 wells-fargo-maintains-overweight-on-globus-medical-raises-price-target-to-79

Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $66 t...

Core News & Articles

FIGS: 19% | FIGS shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY25...

 b-of-a-securities-upgrades-globus-medical-to-buy-raises-price-target-to-91

B of A Securities analyst Craig Bijou upgrades Globus Medical (NYSE:GMED) from Neutral to Buy and raises the price target fr...

 truist-securities-upgrades-globus-medical-to-buy-raises-price-target-to-93

Truist Securities analyst Richard Newitter upgrades Globus Medical (NYSE:GMED) from Hold to Buy and raises the price target ...

 globus-medical-raises-fy2025-adj-eps-guidance-from-300-330-to-375-385-vs-321-est-raises-fy2025-sales-guidance-from-2800b-2900b-to-2860b-2900b-vs-2855b-est

Globus Medical (NYSE:GMED) raises FY2025 Adj EPS guidance from $3.00-$3.30 to $3.75-$3.85 vs $3.21 analyst estimate. Raises FY2...

 globus-medical-q3-adj-eps-118-beats-078-estimate-sales-769048m-beat-734347m-estimate

Globus Medical (NYSE:GMED) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $0.78 by...

 stifel-reinstates-hold-on-globus-medical-announces-64-price-target

Stifel analyst Thomas Stephan reinstates Globus Medical (NYSE:GMED) with a Hold and announces $64 price target.

 carlsmeds-personalized-spine-implants-get-significant-reimbursement-advantage

Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a ...

 wells-fargo-maintains-overweight-on-globus-medical-lowers-price-target-to-66

Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $76 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION